Table 5.
Effects of targeted drugs on caspase 3 activation in neoplastic mast cells
| ED50 (μM) | ||||
|---|---|---|---|---|
| NI-1 | C2 | HMC-1.1 | HMC-1.2 | |
| Bosutinib | >5 | >5 | >5 | >5 |
| Dasatinib | >0.5 | <0.05 | <0.05 | >2 |
| Erlotinib | >5 | >5 | >5 | >5 |
| Everolimus | >5 | >5 | >5 | >5 |
| Gefitinib | >2 | >2 | >2 | >2 |
| Imatinib | >2 | 0.5–1 | 0.01–0.05 | >2 |
| Lapatinib | >2 | >2 | >2 | >2 |
| Masitinib | >2 | 0.5–1 | 0.05–0.1 | >5 |
| Midostaurin | >1 | 0.5–1 | 0.25–0.5 | 0.5–1 |
| Nilotinib | >0.5 | 0.1–0.5 | <0.05 | >2 |
| NVP-BEZ235 | >5 | >5 | 0.05–0.1 | >5 |
| Sunitinib | >2 | <0.5 | <0.05 | >5 |
| Sorafenib | >2 | <0.5 | 0.05–0.1 | >5 |
| Tozasertib | >2 | >2 | 2.5–5 | >5 |
| Vorinostat | 2.5–5 | 2.5–5 | 2.5–5 | >5 |
Cells were incubated with various concentrations of targeted drugs at 37°C for 48 h. Then, the percentage of caspase-3+ cells was determined by flow cytometry. The mean ED50 values from three independent experiments are shown.